Cargando…

Cost-effectiveness of running a paediatric oncology unit in Ethiopia

OBJECTIVE: To estimate the cost-effectiveness of running a paediatric oncology unit in Ethiopia to inform the revision of the Ethiopia Essential Health Service Package (EEHSP), which ranks the treatment of childhood cancers at a low and medium priority. METHODS: We built a decision analytical model—...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiros, Mizan, Memirie, Solomon Tessema, Tolla, Mieraf Taddesse Taddesse, Palm, Michael Tekle, Hailu, Daniel, Norheim, Ole F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016307/
https://www.ncbi.nlm.nih.gov/pubmed/36918241
http://dx.doi.org/10.1136/bmjopen-2022-068210
_version_ 1784907379874201600
author Kiros, Mizan
Memirie, Solomon Tessema
Tolla, Mieraf Taddesse Taddesse
Palm, Michael Tekle
Hailu, Daniel
Norheim, Ole F
author_facet Kiros, Mizan
Memirie, Solomon Tessema
Tolla, Mieraf Taddesse Taddesse
Palm, Michael Tekle
Hailu, Daniel
Norheim, Ole F
author_sort Kiros, Mizan
collection PubMed
description OBJECTIVE: To estimate the cost-effectiveness of running a paediatric oncology unit in Ethiopia to inform the revision of the Ethiopia Essential Health Service Package (EEHSP), which ranks the treatment of childhood cancers at a low and medium priority. METHODS: We built a decision analytical model—a decision tree—to estimate the cost-effectiveness of running a paediatric oncology unit compared with a do-nothing scenario (no paediatric oncology care) from a healthcare provider perspective. We used the recently (2018–2019) conducted costing estimate for running the paediatric oncology unit at Tikur Anbessa Specialized Hospital (TASH) and employed a mixed costing approach (top-down and bottom-up). We used data on health outcomes from other studies in similar settings to estimate the disability-adjusted life years (DALYs) averted of running a paediatric oncology unit compared with a do-nothing scenario over a lifetime horizon. Both costs and effects were discounted (3%) to the present value. The primary outcome was incremental cost in US dollars (USDs) per DALY averted, and we used a willingness-to-pay (WTP) threshold of 50% of the Ethiopian gross domestic product per capita (USD 477 in 2019). Uncertainty was tested using one-way and probabilistic sensitivity analyses. RESULTS: The incremental cost and DALYs averted per child treated in the paediatric oncology unit at TASH were USD 876 and 2.4, respectively, compared with no paediatric oncology care. The incremental cost-effectiveness ratio of running a paediatric oncology unit was USD 361 per DALY averted, and it was cost-effective in 90% of 100 000 Monte Carlo iterations at a USD 477 WTP threshold. CONCLUSIONS: The provision of paediatric cancer services using a specialised oncology unit is most likely cost-effective in Ethiopia, at least for easily treatable cancer types in centres with minimal to moderate capability. We recommend reassessing the priority-level decision of childhood cancer treatment in the current EEHSP.
format Online
Article
Text
id pubmed-10016307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100163072023-03-16 Cost-effectiveness of running a paediatric oncology unit in Ethiopia Kiros, Mizan Memirie, Solomon Tessema Tolla, Mieraf Taddesse Taddesse Palm, Michael Tekle Hailu, Daniel Norheim, Ole F BMJ Open Health Economics OBJECTIVE: To estimate the cost-effectiveness of running a paediatric oncology unit in Ethiopia to inform the revision of the Ethiopia Essential Health Service Package (EEHSP), which ranks the treatment of childhood cancers at a low and medium priority. METHODS: We built a decision analytical model—a decision tree—to estimate the cost-effectiveness of running a paediatric oncology unit compared with a do-nothing scenario (no paediatric oncology care) from a healthcare provider perspective. We used the recently (2018–2019) conducted costing estimate for running the paediatric oncology unit at Tikur Anbessa Specialized Hospital (TASH) and employed a mixed costing approach (top-down and bottom-up). We used data on health outcomes from other studies in similar settings to estimate the disability-adjusted life years (DALYs) averted of running a paediatric oncology unit compared with a do-nothing scenario over a lifetime horizon. Both costs and effects were discounted (3%) to the present value. The primary outcome was incremental cost in US dollars (USDs) per DALY averted, and we used a willingness-to-pay (WTP) threshold of 50% of the Ethiopian gross domestic product per capita (USD 477 in 2019). Uncertainty was tested using one-way and probabilistic sensitivity analyses. RESULTS: The incremental cost and DALYs averted per child treated in the paediatric oncology unit at TASH were USD 876 and 2.4, respectively, compared with no paediatric oncology care. The incremental cost-effectiveness ratio of running a paediatric oncology unit was USD 361 per DALY averted, and it was cost-effective in 90% of 100 000 Monte Carlo iterations at a USD 477 WTP threshold. CONCLUSIONS: The provision of paediatric cancer services using a specialised oncology unit is most likely cost-effective in Ethiopia, at least for easily treatable cancer types in centres with minimal to moderate capability. We recommend reassessing the priority-level decision of childhood cancer treatment in the current EEHSP. BMJ Publishing Group 2023-03-14 /pmc/articles/PMC10016307/ /pubmed/36918241 http://dx.doi.org/10.1136/bmjopen-2022-068210 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Kiros, Mizan
Memirie, Solomon Tessema
Tolla, Mieraf Taddesse Taddesse
Palm, Michael Tekle
Hailu, Daniel
Norheim, Ole F
Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title_full Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title_fullStr Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title_full_unstemmed Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title_short Cost-effectiveness of running a paediatric oncology unit in Ethiopia
title_sort cost-effectiveness of running a paediatric oncology unit in ethiopia
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016307/
https://www.ncbi.nlm.nih.gov/pubmed/36918241
http://dx.doi.org/10.1136/bmjopen-2022-068210
work_keys_str_mv AT kirosmizan costeffectivenessofrunningapaediatriconcologyunitinethiopia
AT memiriesolomontessema costeffectivenessofrunningapaediatriconcologyunitinethiopia
AT tollamieraftaddessetaddesse costeffectivenessofrunningapaediatriconcologyunitinethiopia
AT palmmichaeltekle costeffectivenessofrunningapaediatriconcologyunitinethiopia
AT hailudaniel costeffectivenessofrunningapaediatriconcologyunitinethiopia
AT norheimolef costeffectivenessofrunningapaediatriconcologyunitinethiopia